ARTELO BIOSCIENCES, INC. (ARTL): Nasdaq/NYSE listing notice — Artelo Biosciences receives Nasdaq minimum bid price deficiency notice; 180-day cure period until Oct 20, 2025

ARTELO BIOSCIENCES, INC.

Received Nasdaq notice on April 23, 2025 for non-compliance with $1.00 minimum bid price requirement.
Must regain compliance by Oct 20, 2025; closing bid price must meet or exceed $1.00 for 10 consecutive business days.
Possible second 180-day extension if other listing standards met; company may implement a reverse stock split.
No immediate effect on listing; company intends to monitor bid price and evaluate available options.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ARTELO BIOSCIENCES, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

April 23, 2025, Artelo Biosciences, Inc. (the “ Company ”) received written notice from The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until October 20, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, subject to Nasdaq’s discretion, the closing bid price of the Compa

View on SEC.gov

Browse all listing & compliance notices →

ARTELO BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001640334-25-000719

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.